Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS):study protocol for a randomized controlled trial by Sullivan, F. M. et al.
                                                              
University of Dundee
Detection in blood of autoantibodies to tumour antigens as a case-finding method in
lung cancer using the EarlyCDT®-Lung Test (ECLS)
Sullivan, F. M.; Farmer, Eoghan; Mair, Frances S.; Treweek, Shaun; Kendrick, Denise;
Jackson, Cathy; Robertson, Chris; Briggs, Andrew; McCowan, Colin; Bedford, Laura; Young,
Ben; Vedhara, Kavita; Gallant, Stephanie; Littleford, Roberta; Robertson, John; Sewell, Herb;
Dorward, Alistair; Sarvesvaran, Joseph; Schembri, Stuart
Published in:
BMC Cancer
DOI:
10.1186/s12885-017-3175-y
Publication date:
2017
Document Version
Final published version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Sullivan, F. M., Farmer, E., Mair, F. S., Treweek, S., Kendrick, D., Jackson, C., ... Schembri, S. (2017). Detection
in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-
Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17, 1-10. [187]. DOI:
10.1186/s12885-017-3175-y
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
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Detection in blood of autoantibodies to
tumour antigens as a case-finding method
in lung cancer using the EarlyCDT®-Lung
Test (ECLS): study protocol for a
randomized controlled trial
F. M. Sullivan1*, Eoghan Farmer2, Frances S. Mair3, Shaun Treweek4, Denise Kendrick5, Cathy Jackson6,
Chris Robertson7, Andrew Briggs8, Colin McCowan9, Laura Bedford10, Ben Young10, Kavita Vedhara5,
Stephanie Gallant11, Roberta Littleford12, John Robertson13, Herb Sewell14, Alistair Dorward15,
Joseph Sarvesvaran16 and Stuart Schembri17
Abstract
Background: Lung cancer is the most common cause of cancer related death worldwide. The majority of cases are
detected at a late stage when prognosis is poor. The EarlyCDT®-Lung Test detects autoantibodies to abnormal cell
surface proteins in the earliest stages of the disease which may allow tumour detection at an earlier stage thus altering
prognosis.
The primary research question is: Does using the EarlyCDT®-Lung Test to identify those at high risk of lung
cancer, followed by X-ray and computed tomography (CT) scanning, reduce the incidence of patients with
late-stage lung cancer (III & IV) or unclassified presentation (U) at diagnosis, compared to standard practice?
Methods: A randomised controlled trial of 12 000 participants in areas of Scotland targeting general practices
serving patients in the most deprived quintile of the Scottish Index of Multiple Deprivation. Adults aged 50–75 who are
at high risk of lung cancer and healthy enough to undergo potentially curative therapy (Performance Status 0–2) are
eligible to participate. The intervention is the EarlyCDT®-Lung Test, followed by X-ray and CT in those with a positive
result. The comparator is standard clinical practice in the UK. The primary outcome is the difference, after 24 months,
between the rates of patients with stage III, IV or unclassified lung cancer at diagnosis. The secondary outcomes
include: all-cause mortality; disease specific mortality; a range of morbidity outcomes; cost-effectiveness and
measures examining the psychological and behavioural consequences of screening.
Participants with a positive test result but for whom the CT scan does not lead to a lung cancer diagnosis will be
offered 6 monthly thoracic CTs for 24 months. An initial chest X-ray will be used to determine the speed and the need
for contrast in the first screening CT. Participants who are found to have lung cancer will be followed-up to assess both
time to diagnosis and stage of disease at diagnosis.
(Continued on next page)
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Discussion: The study will determine the clinical and cost effectiveness of EarlyCDT®-Lung Test for early lung cancer
detection and assess its suitability for a large-scale, accredited screening service. The study will also assess the potential
psychological and behavioural harms arising from false positive or false negative results, as well as the potential benefits
to patients of true negative EarlyCDT lung test results. A cost-effectiveness model of lung cancer screening based on
the results of the EarlyCDT Lung Test study will be developed.
Trial registration: NCT01925625. August 19, 2013
Keywords: Lung cancer, Early diagnosis, Screening, Health economics, RCT, Primary care, Biomarker, Autoantibodies
Background
Lung cancer is the world’s leading cause of cancer related
mortality and a major source of morbidity [1]. It is often di-
agnosed at an advanced stage with 85% of patients undiag-
nosed until the disease is symptomatic [2]. Scotland has
one of the highest rates of lung cancer in the world [3].
Around 2 460 men and 2 340 women are diagnosed with
lung cancer in Scotland every year, which is 16% of the total
UK cases, despite Scotland having only 8% of the UK’s
population. Survival from lung cancer is poor with less than
9% of patients still alive at 5 years after diagnosis, due pri-
marily to the late stage of presentation [4]. Early detection
and diagnosis of cancer improves prognosis - the current 5-
years survival rate is approximately 60% for stage I lung
cancer but is only 1% for those with stage IV disease [5].
The first studies evaluating screening for lung cancer
utilised chest X-ray and/or sputum cytology [6–9].
While these showed increased numbers of earlier-stage,
resectable cancers and improved survival rates in the
screened groups, not all studies were randomised. The
lack of trial strength data means that differences in lung
cancer mortality between those screened and those not
are difficult to interpret.
The National Cancer Institute National Lung Screen-
ing Trial (NLST) reported that CT screening reduced
lung cancer mortality by 20% [10]. This has led to a
number of guidelines in the United States which advo-
cate lung cancer screening with low dose CT [11]. How-
ever as a primary screening modality CT is expensive
and leads to a significant percentage of false positives
(>90% of nodules are found to be benign) [12]. There
was a substantial increase in morbidity associated with
further investigation. More recently the UK Lung Cancer
Screening Trial reported successful early detection of
lung cancer using low dose CT scans [13].
The EarlyCDT®-Lung Test is a novel Autoantibody(-
AAB) diagnostic test for the early detection of lung cancer
allowing stratification of individuals according to their risk
of developing lung cancer [14]. This could permit a tar-
geted approach to CT scanning for early lung cancer de-
tection which may be a more cost-effective and potentially
less harmful approach to population screening.
The EarlyCDT®-Lung Test measures seven AABs; p53,
NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 & SOX2.
It identifies 41% of lung cancers with a high specificity
of 90% [14]. This compares to CT scanning, which when
used alone as a prevalence screening test, identifies 67%
of lung cancers developing over the following 12 months,
but has a low specificity of around 49% [10]. The auto-
antibodies detected in the test have not been shown to
vary with age, gender and ethnicity [15].
In a large group of patients (n = 3 376) with newly di-
agnosed lung cancers there was no difference in positiv-
ity rate for the test in early or late stage disease lung
cancers, and this applied to all lung cancers [14, 16].
Thus, while autoantibodies are present in early stage
they are not simply a biomarker of early stage disease.
While preliminary data shows promise there is insuffi-
cient evidence, as yet, to support the introduction of this
test for cancer screening or a case finding program.
Consequently, the primary research question is: ‘Does
using the EarlyCDT®-Lung Test, followed by X-ray and
CT scanning, to identify those at high risk of lung cancer
reduce the incidence of patients with late-stage lung
cancer (III & IV) or unclassified presentation (U) at
diagnosis, compared to standard clinical practice?
AIMS
To assess the effectiveness of the test in increasing early
stage lung cancer detection, thereby reducing the rate of
late stage (III/IV/U) presentation compared to standard
practice; to assess the cost-effectiveness of the test com-
pared to standard practice; to assess the impact of the
test on quality of life, positive and negative affect, illness
perceptions, lung cancer risk perception, health anxiety,
lung cancer worry, subjective stress related to screening,
smoking behaviour and health service use.
Methods
Design
This is a randomised controlled trial involving 12,000 par-
ticipants recruited through primary care and community
based recruitment strategies in Scotland. < h3 > Setting.
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General practices who serve patients in the lowest
quintile of deprivation in Scotland, as measured by the
Scottish Index of Multiple Deprivation, will be targeted
[17]. Additional recruitment will be attained through ad-
verts, posters, flyers and community based interactions
and may extend to other practices as needed to ensure
reaching our recruitment targets. Potential participants
can either be seen at their participating GP practice or
at the local clinical research centre, or other appropriate
clinical location.
Participants
Adults aged 50–75 who have at least a 2% risk of devel-
oping lung cancer over the next 24 months will be eli-
gible to participate [18]. These are defined as those who
are, current or former cigarette smokers with at least 20
pack-years, or have a history of cigarette smoking less
than 20 pack-years plus an immediate family history
(mother, father, brother, sister, child) of lung cancer
which gives an individual a personal risk similar to a
smoking history of 20 pack years. Participants should be
healthy enough to undergo radical treatment either by
pulmonary resection or stereotactic radiotherapy.
Number of participants
We will recruit 12,000 participants, from approximately
170 general practices.
Inclusion criteria
1. Participant is willing and able to give informed
consent for participation in the study
2. Male or female aged 50–75 years
3. Current or Ex-smoker with at least 20 years pack
history
4. Less than 20 years pack history but with family
history of lung cancer in a 1st degree relative
(mother, father, sister, brother, child)
5. Eastern Co-operative Oncology Group Status: 0, 1
and 2 [19]
Exclusion criteria
1. History of any cancer other than non-melanomatous
skin cancer and/or cervical cancer in situ.
2. Complaining of symptoms suggestive of lung cancer
within past 6 months i.e. haemoptysis or weight loss.
3. Patients for whom the GP considers invitation to the
study would cause undue distress.
4. Patients with terminal disease.
5. Patients on prolonged/continuous use (>3 months)
of Cyclophosphamide.
Randomisation
Participants will be allocated to the intervention or com-
parison group during the recruitment visit (Visit 1) using
a web-based randomisation system TRuST [20]. Ran-
domisation will be stratified by site and minimised by
age, sex and smoking history.
Dates and duration of trial
01/08/2013–31/07/18 (60 months).
Identifying participants
Practices in the most deprived areas will be approached
by facilitators in the Scottish Primary Care Research
Network (SPCRN) to participate. Potentially eligible in-
dividuals will be identified from GP medical records by
an electronic medical record search [21]. Potential par-
ticipants will be recruited via their General Practitioner
and a range of other methods as recommended by the
pre-trial focus groups [22]:
 postal invitation letter including a summary of the
study Participant Information Sheet and a full
Participant Information Sheet or Participant
Information Brochure for those interested;
 invitation letter including a summary of the study
Participant Information Sheet on collection of repeat
prescription;
 invitation during consultation with GP/Practice
Nurse/Health Care Assistant at the practice;
 invitation to those eligible on registered research
volunteer databases
 poster present in the GP’s waiting room
 media campaign involving:
◦ local and national newspaper
◦ radio
◦ celebrity endorsement
◦ publicity campaign using posters/leaflets
The study invitation letter will include a slip for partic-
ipants to either express interest in finding out more
about the study [23]. Those returning an expression of
interest will be telephoned, more than 24 h after antici-
pated receipt of the Participant Information Sheet, by a
member of the research team. The call will allow a dis-
cussion of the study, to answer any questions the poten-
tial participant may have, do a preliminary assessment of
eligibility and if agreed, to make an appointment for a
recruitment visit. An appointment letter/email will be
sent out to confirm appointment. A reminder call/email
or text, whichever is preferable to the participant, will be
carried our 2 days prior to the screening appointment to
reduce non-attendance [24]. Non-responders to the
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postal invite will be contacted by letter again once or via
a message on the right side of a repeat prescription [25].
Those returning an expression of interest will be sent a
full information sheet and dealt with as above.
Initial consultation
The following procedures will be undertaken in the
order given below:
 obtain consent
 take bloods from all consented participants
 complete study questionnaire
 randomise to treatment arm
Administration of the test
After randomisation, all participants will be asked if they
still wish to take part in the trial and still agree for their
bloods to be used for the test and for future cancer re-
lated research. For participants randomised to the inter-
vention arm the EarlyCDT®-Lung test will be performed
and patients followed up according to their result (see
Additional file 1: study flowchart).
At the initial visit, participants are told that those with
a positive EarlyCDT®-Lung Test result will be invited to
a follow-up visit to discuss the test results and explain
what happens next. Those with a negative EarlyCDT®-
Lung Test result will receive a letter explaining the test
results and will be offered a follow-up visit or a tele-
phone call if they wish. They will be told that the best
way to reduce risk of developing lung cancer is by stop-
ping smoking and that symptoms to watch for include
persistent cough, coughing up blood, shortness of
breath, weight loss or loss of appetite.
Those in the control arm will be written to and thanked
for their contribution to the study and advised and coun-
selled identically to those in the intervention arm who
have had a negative EarlyCDT®-Lung Test result.
A patient specific section of the study website
(www.eclsstudy.org) containing Participant Information
Sheets and research staff contact details will be available
for participants.
Management of the visits
Based on the test’s reported 90% specificity and 41% sensi-
tivity we anticipate that 520–550 participants in the inter-
vention arm will have a positive test result. These will be
offered a chest X-ray in accordance with local require-
ments for prioritisation and will be referred for a non-
contrast thoracic CT scan. If there is a suspicious opacity
on the chest X-ray or initial CT scan a contrast enhanced
staging CT will be undertaken. As a quality control meas-
ure no participant undergoing CT screening in the test
positive arm will have all their 5 CTs reported by same
radiologist. Nodule size will be currently reported as the
mean of 2 diameters at 90° angles, volumetric analysis is
starting soon on both sites with diameter and volume to
be reported. If the initial CT scan reveals no evidence of
lung cancer then subsequent CT scans will be offered 6
monthly for 24 months. An appointment window of ±
4 weeks will be initiated for each scheduled CT scan.
If a test positive participant has had a chest X-ray in the
previous 1 month, or a CT scan in the previous 3 months,
these can be reviewed as part of the study. With the par-
ticipant’s consent chest X-rays or CT scans prior to study
entry will be retrospectively coded. The participant will
proceed to have the series of up to 5 CTs.
Participants will receive appointments via post/email,
according to patient preference. Participants will be called
2–4 days before each CT scan appointment. Individuals
with abnormalities as classified by the radiology/respira-
tory physician’s study panel on baseline CT scan or subse-
quent CT scan will be followed up over the study period
or referred for NHS clinical care as appropriate. All indi-
viduals entering the study will be flagged and followed-up
via the Scottish Cancer Registry in the Electronic Data Re-
search and Innovation Service (eDRIS) [26]. Participants
who develop lung cancer will be followed-up via their
medical records to assess both time to diagnosis and stage
of disease at diagnosis. If no histological stage is available,
stage will be assessed by a panel of three respiratory physi-
cians blind to allocation status of the study subjects from
chest X-rays or CT, or if no imaging is available, medical
assessment of stage will be carried out.
Prior to sending CT scan appointment dates, the Scot-
tish Community Health Index national register will be
checked for vital status. All participants in the test- Posi-
tive test groups known to have died will be removed
from the CT scan appointment schedule register. If pa-
tients (positive test) fail to attend for any imaging assess-
ment during the study, they will receive two reminders
(one letter, one phone call). On the third non-
attendance, a letter will be sent to the participant’s GP
to inform them of non-attendance.
Participants will receive results letters in relation to
their initial chest X-ray and CT scan and subsequent CT
scans. Any clinical intervention/treatment will be ar-
ranged by the relevant NHS multidisciplinary team.
Control
The comparator is UK standard clinical practice which
involves awaiting the development of symptoms and in-
vestigation of those symptoms according to national
guidelines [27, 28].
Intervention
EarlyCDT®-Lung Test blood sample followed by X-ray
and serial cross sectional CT imaging in those with a
positive result 6 monthly for 24 months. Those with a
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negative test, like the controls, have no further investiga-
tions but are provided with standard clinical care.
Outcomes
Primary
The difference, at 24 months after randomisation, be-
tween the rates of patients with stage III, IV or unclassi-
fied lung cancer at diagnosis in the intervention arm,
and those in the control arm;
Secondary
1. numbers at 24 months after randomisation, in the
different stages at diagnosis (III/IV/U/other) in the
intervention arm and the control arm;
2. difference, after 24 months, between costs and
outcomes between the intervention arm and in the
control arm and cost-effectiveness of the test compared
to standard practice;
3. differences, after 24 months, of lung cancer
mortality, all-cause mortality and cancer-specific
mortality rates between the intervention arm and in
the control arm;
4. differences, after 5 and 10 years, of long-term future
mortality rates in the intervention arm and in the
control arm;
5. differences, after 24 months in (i) the number of
patients with stage III, IV or unclassified lung cancer
at diagnosis in the test-positive group and those in
the test-negative group and (ii) stage at diagnosis in
the test-positive and test-negative group;
6. difference between the test-positive, test-negative
groups and the control arm at 1, 3, 6, and 12 months
in scores for EQ5D [29], Positive and Negative
Affect Schedule [30], revised Illness Perception
Questionnaire adapted to refer to lung cancer and
lung cancer risk [31], Lung cancer risk perception,
Health anxiety subscale of Health Orientation Scale
[32], the Adapted Lung Cancer Worry Scale [33]
and Impact of Events Scale [34] (for the test-positive
group, the test-negative group only) and differences
in smoking behaviour and health service use. Long-
term scores for the same outcomes for the test-
positive group at 18 and 24 months;
7. difference in incidence at 24 months, and after 5 and
10 years, in other clinical measures such as
Cerebrovascular disease, Chronic Obstructive
Pulmonary Disease, hospital stays, and outcomes
identified through the Scottish Morbidity Record
(SMR) linkage in the intervention arm and in the
control arm
8. numbers in all groups at 24 months (test-positive,
test-negative and control) undertaking subsequent
investigations such as chest X-ray, CT and
bronchoscopy (Table 1)
Statistics and data analysis
Sample size calculations
Main study The rate of lung cancer was 187/100,000
per year for patients aged 50–74 in Scotland 2008 which
is higher than many other similar countries [23].
Deprivation is associated with a significantly higher risk
of lung cancer. Living in the most deprived quintile is
associated with an increased risk of 1.8 times compared
to the middle quintile of deprivation; this gives an esti-
mated annual lung cancer rate of 336/100,000 among
the practices taking part in the study. A high risk group
within this population will be selected using similar
entry criteria (outlined above) as the Mayo screening
study which had a 2% prevalence rate of lung cancer and
a further 2% incidence rate over the following 5 years
[35]. The baseline rate of late stage presentation for the
particular high risk population envisaged in this study is
uncertain, as is the size of the reduction in late stage
presentation likely to be achieved through use of Ear-
lyCDT®-Lung Test. Using an estimated late stage presen-
tation rate of 1,200/100,000 per year in the control arm
i.e. 2.4% over the 2-years follow-up period, provides 85%
power at 5% significance (two-sided) to detect an esti-
mated reduction of 35% in late stage presentation rate in
the intervention arm i.e. as low as 780/100,000 per year
or 1.56% over the 2-years follow-up period. This corre-
sponds to an estimated event rate over the 24 months of
follow-up of 120 events in the control arm and 78 events
in the intervention arm and implies a required sample
size of 5,000 per arm i.e. a total of 10,000 participants.
The anticipated 35% reduction in event rate between
the control arm and the intervention arm was justified
by current estimates of the capability of the test to iden-
tify cases together with current estimates of the sensitiv-
ity of CT scanning (67%). The assumed event rate in the
study participants of 1.2% per year was an estimate and
the sample size would be modified if the observed
event rate proves to be markedly different, acknow-
ledging the a priori possibility that we will employ a
prospective adaptive design. No Interim analysis of ef-
ficacy is planned.
The sample size calculations are based upon standard
methods for time to event data using the c power func-
tion in R and st power exponential procedure in Stata
and assuming exponential survival [34, 36]. They were
also confirmed using standard approaches for detecting
a change in binomial probabilities, and confirmed using
approaches to detect a change in Poisson rates (with es-
sentially identical results as loss to follow up is expected
to be low due to completeness of Scottish Morbidity
Register data).
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The study aims for a short recruitment period and so
no allowance has been made for accrual. With such an
allowance, say to 1 year, the power will increase to 91%
to identify a 35% reduction provided the minimum fol-
low up period of 2 years is observed.
The initial assumptions of the rate of late stage presen-
tation rate of 1,200/100,000 per year among the study par-
ticipants was too optimistic and in January to May 2015
investigations were carried out to inform an increase in
the sample size. Baseline information on the 8639 partici-
pants recruited to March 2015 (18 months from first ran-
domisation) was used to derive an estimate of lung cancer
risk based upon the Spitz Model. A number of variables in
this model were not recorded in the study data base and
low risk values were used in the risk calculation implying
that the risk estimates should be underestimates. This sug-
gested that the with 10,000 participants the rate of lung
cancer would be expected to be around 680/100,000 and
540/100,000 for stage T3/T4/Unknown lung cancer using
ISD cancer statistics figures of 80% lung cancers in
Scotland are late stage. A sensitivity analysis around the
missing data assumptions suggests that a late stage rate of
around 600/100,000 may not be unreasonable, though is
likely to be at the upper limit.
Using an assumption of 600/100,000 for late stage
lung cancer, increasing the sample size to 12,000 [37],
and acknowledging that recruitment is over a 2 years
period the study has a power of 80% to detect a 35%
reduction associated with the use of the EarlyCDT-
Lung test to identify cases, provided that analysis takes
place after all randomised patients have been followed
up for 2 years. While an 80% power is at the lower
end of acceptable powers this is the power level which
has been used in a number of lung cancer screening
trials.
The power of the study is sensitive to the assumptions
about the rate of late stage cancer and the recruitment
rate. A power in excess of 90% could only realistically be
achieved by recruiting 15,000 patients or by changing
the primary endpoint to 3 years post randomisation for all
patients. If the recruitment phase extends past 2–2.5 years
to recruit 12,000 participants then the power will increase
slightly to 83%.
Substudies For the follow-up analysis of behavioral and
psychological outcomes, 200 participants in each group
(test-positive, test-negative and the control arm) will
allow detection of a mean difference of 3.00 (SD 15.04
Table 1 Data Collection Timeline
Assessment/Procedures Timeline (± 2 weeks)
Visit 1
(~30-45mins)
Visit 2
(~30mns)
➢ EarlyCDT Positive Test Participants may visit or call.
➢ EARLY CDT Negative Test Participants may attend for
further information/advice only.
Informed Consent X
Inclusion/Exclusion Criteria X
• Review/Record only Relevant Medical
History relating to IC/EC
X
• Review/Record Relevant Medications
• Relating to IC/EC
X
Blood Sample X
Baseline Questionnaire X
Thank you letter to Control Group X
EarlyCDT- Lung Test Result Letter X
GP Results Letter & ICF copy (negative) X
Result Discussion/ Imaging Schedule X
Provide PIS 2 X
GP Result Letter & ICF copy (positive) X
EarlyCDT – Lung Test Positive Result
Participants – Imaging Schedule
Timeline(± 12 weeks)
0 6 months 12 months 18 months 24 months
CXR X
CT Scan X X X X X
Scheduled every 6 months, if participant enters
NHS clinical care pathway, subsequent study CT
scans will be cancelled.
Research team member will call 2–4 days before each scheduled CT
scan to check health status and attendance.
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(unpublished data comparing pre and post prostate
biopsy scores from the ProtecT prostate cancer study))
in the Impact of Events Scale between baseline and
follow up measurements. (http://www.ncbi.nlm.nih.gov/
pubmed/21047592) This study reported within each
group and a mean difference of 4.2 (SD 15.04), between
each of the test groups and the control arm with 80%
power and 2-sided 5% significance level. Assuming 80% of
participants are current smokers, this will provide 80%
power at 5% significance level to detect a 13% point differ-
ence in the prevalence of smoking between each of the test
groups and the control arm (i.e. from 80 to 67%) To allow
for attrition, we will recruit 300 participants in each group.
Proposed analyses
Characteristics of participants will be compared informally
between treatment arms at baseline. The main analysis of
the primary outcome will be intention-to-treat. Cox pro-
portional hazards models which will be used to estimate
the hazard ratio of the rate of late stage lung cancer in the
intervention arm compared to the control arm. Partici-
pants who are lost to follow up will be censored. The
models will adjust for age, gender smoking history, socio-
economic status and practice. If appropriate, random clus-
ter effects will be included rather than fixed effects for
practices. A similar methodology will be used for the sec-
ondary outcomes of comparisons of mortality rates. A sub-
sequent analysis will compare the outcomes of those with
a positive test in comparison to those in the intervention
group with a negative test (primary contrast for this ana-
lysis) and those in the control group. Comparisons of pro-
portions will be carried out using chi square tests. Fisher’s
exact test will be used if the number of events is small.
Psychological and behavioral outcomes will be com-
pared between the three groups (Test-positive, Test-
negative and the control group) at baseline using analysis
of variance (or non-parametric tests if there is evidence of
non-normal distribution of scores) for continuous mea-
sures and χ2 tests for categorical measures. Psychological
(HADS Score) and behavioral measures will be described
at each follow up time point and multilevel regression
models will be used for analyses to take account of re-
peated measurements during follow up [38].
Poisson regression models, adjusting for follow up
time if necessary, will be used to investigate the other
clinical measures (secondary outcomes 7 and 8).
Cost effectiveness analysis
A short-term within-trial analysis will compare the costs
and outcomes associated with the intervention arm to
those of the comparison arm at 24 months, with a focus
on cost-per-case detected. A longer term analysis will
employ a decision analytic model to link the short term
outcomes measured within the trial to potential longer
term impacts on health, in terms of impacts on morbid-
ity and mortality of early detection and treatment, to
allow the estimation of cost-per Quality Adjusted Life
Years gained. Both analyses will take the perspective of
the NHS and personal social services and conform to
the reference case favoured by NICE [39].
Missing data
The extent of missing data will be examined and, if ne-
cessary, methods such as multiple imputation will be im-
plemented to assess the robustness of results to missing
data, assuming data are missing at random.
End of study
The end of study is defined as last patient last visit test-
related scan plus 24 months. The Sponsor, CI and/or the
Trial Steering Committee have the right at any time to ter-
minate the study for clinical or administrative reasons.
Data collection & management
Data collection
All research blood samples will be transported to the
University of Nottingham for processing, and then trans-
ported to the US for Test processing by Oncimmune.
All samples will be stored under custodianship as per
UK Biobank guidelines [40]. Sample Analysis and Chain
of Custody Plans are documented in the Study Opera-
tions Manual. The participant’s medical notes (GP and
hospital) paper or electronic will act as source data for
relevant past medical history, subsequent medical condi-
tions, hospital admissions and diagnostic reports.
Psychological and behavioural data will be collected on
the first 10,000 participants through a baseline question-
naire administered during Visit 1. Follow-up data will be
collected between 1 and 12 months on subsets of the
intervention and control arms and at 18 and 24 months
for the EarlyCDT®-Lung Test-positive group. Data col-
lected at baseline will include the EQ5D, Hospital Anx-
iety and Depression Scale, Positive and Negative Affect
Schedule, revised Illness Perception Questionnaire
adapted to refer to lung cancer and lung cancer risk,
lung cancer risk perception, items from the Health
Orientation Scale, the adapted Lung Cancer Worry
Scale, smoking behaviour and demographic details.
Follow-up questionnaires include the same measures,
plus health service use and Impact of Events Scale and
health service use for those who had the test. The Hos-
pital Anxiety and Depression Scale is not included in
follow-up questionnaires and the EQ-5D is not included
in the 3 months follow-up questionnaire.
All participants in the positive group will be
approached with the recruitment aim of 300 from this
group. The TCTU will use an electronic randomisation
tool to randomly sample patients from the test-negative
Sullivan et al. BMC Cancer  (2017) 17:187 Page 7 of 10
group and control arm, stratified by the two study cen-
tres. Twenty-one individuals will be sampled each week
and invited to complete follow-up questionnaires with
an aim of recruiting 300 from both groups (based on an
anticipated response rate of 67%).
Participants who receive a diagnosis of lung cancer will
not be followed up subsequent to receiving the diagnosis.
Data management and data management system
Data will be collected by the RN either directly onto a
paper CRF with subsequent transcription to the eCRF,
or direct data entry onto the web based eCRF.
TCTU will provide a data management system using
OpenClinica [41]. The data management system will be
fully validated, including the provision of test data and
supporting documentation. Backup and disaster recovery
will be provided by TCTU according to its standard op-
erating procedures [42].
The Statistical Analysis Plan will specify dummy tables
linked to primary and secondary outcomes and the data
management system will be designed to export directly
to the dummy table formats for analysis.
Safety assessments
Adverse Events (AE) and Serious Adverse Events (SAE)
will be recorded. A number of factors affecting the trial
population suggest that we would expect to observe a
larger than normal incidence of episodes of ill-health
due to both the age and co-morbidities of the study
population. All chest X-ray and CT scan incidental find-
ings will be recorded in the CRF as an incidental finding
and a specialist referral will be made as directed in a
study Standard Operating Procedure (SOP) within the
Study Operations Manual [43]. AEs (as defined) will be
recorded as soon as they are known either from the
study subjects, PI patient review audits or via SMR or
record review.
Ethical considerations
The study will be conducted in accordance with the
principles of good clinical practice (GCP) and the Re-
search Governance Framework Scotland [44].
Confidentiality
All records will be kept in a secure storage area with
limited access to study staff only. Clinical information
will not be released without the written permission of
the participant, except as necessary for monitoring and
auditing by the Sponsor, its designee or Regulatory
Authorities.
Data protection
The CI and study staff involved with this study will com-
ply with the requirements of the Data Protection Act
1998 with regard to the collection, storage, processing
and disclosure of personal information and will uphold
the Act’s core principles. The CI and study staff will also
adhere to the current version of the NHS Scotland Code
of Practice on Protecting Patient Confidentiality and all
other governance requirements. Published results will
not contain any personal data that could allow identifi-
cation of individual participants.
Insurance and indemnity
The University of Dundee and Tayside Health Board are
Co-Sponsoring the study.
Discussion
Despite advances in surgical techniques, radiation ther-
apy and systemic therapy the outlook for patients with
lung cancer has improved more slowly than many other
cancers over the last 50 years. Early diagnosis of treat-
able disease is likely to be the major way of changing
outcomes for the foreseeable future. The study will as-
sess the EarlyCDT®-Lung Test’s clinical suitability and
cost effectiveness for a large-scale, accredited screening
service for early lung cancer detection. It will also assess
potential morbidity arising from the test and potential
psychological and behavioural harms and benefits of
test results.
The major strength of this trial lies within its design.
By being both randomised and controlled many of the
inherent biases that affected many of the previous
screening studies will be removed. Our trial will also be
able to investigate the effect of either a positive or nega-
tive result on participants’ lifestyle decisions to explore
whether a negative result reinforces harmful behaviour,
such as smoking, or a positive result reduces harmful be-
haviour. To date, screening with low dose CT scanning
does not appear to have a beneficial effect on smoking
behaviour [38, 45–47]. As in many screening studies a
potential weakness is that the study population may be
different to the usual clinical populations in terms of
age, smoking status and education. Our eligibility criteria
ensure participants have a high risk of lung cancer over
the subsequent 24 months and our findings should be
generalisable to populations with a similar level of risk.
Our focus on areas with high levels of deprivation for re-
cruitment should help ensure our participants reflect the
social gradient in lung cancer incidence and our collec-
tion of demographic data will enable us to compare the
characteristics of our trial population with those at risk
of lung cancer.
One potential weakness is that participants rando-
mised to the control arm may change their behaviour to
decrease their risk of lung cancer e.g. by stopping smok-
ing in a way that they would not have done had they not
been participating in our study. The lack of impact of
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screening using CT scanning on smoking behaviour sug-
gests this may not occur to an important extent, but
measurement of smoking behaviour at repeated follow
up time points will enable us to quantify this and assess
its impact on our findings.
Trial status
Recruitment began the 7th of August 2013.
Additional file
Additional file 1: Figure schedule of enrolment, interventions, and
assessments. (DOC 53 kb)
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